117 related articles for article (PubMed ID: 11510147)
1. [Plasminogen activators of urokinase and tissue types and their inhibitor (PAI-1) in cytosol fraction in thyroid diseases].
Kushlinskiĭ NE; Gershteĭn ES; Kazantseva IA; Kharitidi TIu; Liakina LT; Kazakov SP; Bagatyrev OP; Kalinin AP
Vestn Ross Akad Med Nauk; 2001; (5):32-4. PubMed ID: 11510147
[TBL] [Abstract][Full Text] [Related]
2. [Urokinase and tissue type plasminogen activators and their type-1 inhibitor (PAI-1) in gastric cancer].
Gerstein ES; Shcherbakov AM; Kaz'min AI; Ognerubov NA; Kushlinskiĭ NE
Vopr Onkol; 2003; 49(2):165-9. PubMed ID: 12785198
[TBL] [Abstract][Full Text] [Related]
3. ELISA for complexes of urokinase-type and tissue-type plasminogen activators with their type-1 inhibitor (uPA-PAI-1 and tPA-PAI-1).
Grebenschikov N; Sweep F; Geurts A; Andreasen P; De Witte H; Schousboe S; Heuvel J; Benraad T
Int J Cancer; 1999 May; 81(4):598-606. PubMed ID: 10225451
[TBL] [Abstract][Full Text] [Related]
4. A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type I (PAI-1) in breast tumor cytosols.
Grebenschikov N; Geurts-Moespot A; De Witte H; Heuvel J; Leake R; Sweep F; Benraad T
Int J Biol Markers; 1997; 12(1):6-14. PubMed ID: 9176711
[TBL] [Abstract][Full Text] [Related]
5. Urokinase plasminogen activator and its inhibitor type-1 as prognostic factors in differentiated thyroid carcinoma patients.
Horvatic Herceg G; Herceg D; Kralik M; Kulic A; Bence-Zigman Z; Tomic-Brzac H; Bracic I; Kusacic-Kuna S; Prgomet D
Otolaryngol Head Neck Surg; 2013 Oct; 149(4):533-40. PubMed ID: 23835563
[TBL] [Abstract][Full Text] [Related]
6. Urokinase-type plasminogen activator and its inhibitor in thyroid neoplasms: a cytosol study.
Horvatić Herceg G; Herceg D; Kralik M; Bence-Zigman Z; Tomić-Brzac H; Kulić A
Wien Klin Wochenschr; 2006 Oct; 118(19-20):601-9. PubMed ID: 17136335
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.
Borstnar S; Vrhovec I; Svetic B; Cufer T
Clin Breast Cancer; 2002 Jun; 3(2):138-46. PubMed ID: 12123538
[TBL] [Abstract][Full Text] [Related]
8. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
[TBL] [Abstract][Full Text] [Related]
9. Clinical value of components of the plasminogen activation system in ovarian cyst fluid.
Boss EA; Massuger LF; Thomas CM; Geurts-Moespot A; van Schaik JH; Boonstra H; Sweep CG
Anticancer Res; 2002; 22(1A):275-82. PubMed ID: 12017303
[TBL] [Abstract][Full Text] [Related]
10. Plasminogen activator inhibitor-1 in neointima of vein grafts: its role in reduced fibrinolytic potential and graft failure.
Kauhanen P; Sirén V; Carpén O; Vaheri A; Lepäntalo M; Lassila R
Circulation; 1997 Sep; 96(6):1783-9. PubMed ID: 9323062
[TBL] [Abstract][Full Text] [Related]
11. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
Grøndahl-Hansen J; Christensen IJ; Rosenquist C; Brünner N; Mouridsen HT; Danø K; Blichert-Toft M
Cancer Res; 1993 Jun; 53(11):2513-21. PubMed ID: 8388317
[TBL] [Abstract][Full Text] [Related]
12. Expression and prognostic significance of urokinase and plasminogen activator inhibitor type-1 in endometrial hyperplasia and cancer.
Taponeco F; Curcio C; Giuntini A; Nardini V; Fornaciari G; Artini PG; D'Ambrogio G; Genazzani AR
J Exp Clin Cancer Res; 2001 Jun; 20(2):239-46. PubMed ID: 11484981
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients.
de Witte JH; Sweep CG; Klijn JG; Grebenschikov N; Peters HA; Look MP; van Tienoven TH; Heuvel JJ; van Putten WL; Benraad TJ; Foekens JA
Br J Cancer; 1999 Mar; 79(7-8):1190-8. PubMed ID: 10098758
[TBL] [Abstract][Full Text] [Related]
14. Plasminogen activator levels are influenced by location and varicosity in greater saphenous vein.
Shireman PK; McCarthy WJ; Pearce WH; Shively VP; Cipollone M; Kwaan HC; Yao JS
J Vasc Surg; 1996 Nov; 24(5):719-24. PubMed ID: 8918314
[TBL] [Abstract][Full Text] [Related]
15. Plasminogen activators and inhibitors in gliomas: an immunohistochemical study.
Caccamo DV; Keohane ME; McKeever PE
Mod Pathol; 1994 Jan; 7(1):99-104. PubMed ID: 8159659
[TBL] [Abstract][Full Text] [Related]
16. Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors.
van der Burg ME; Henzen-Logmans SC; Berns EM; van Putten WL; Klijn JG; Foekens JA
Int J Cancer; 1996 Dec; 69(6):475-9. PubMed ID: 8980250
[TBL] [Abstract][Full Text] [Related]
17. Plasminogen activator system in oral squamous cell carcinoma.
Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
[TBL] [Abstract][Full Text] [Related]
18. High concentrations of plasminogen activator inhibitor-1 in lungs of preterm infants with respiratory distress syndrome.
Cederqvist K; Sirén V; Petäjä J; Vaheri A; Haglund C; Andersson S
Pediatrics; 2006 Apr; 117(4):1226-34. PubMed ID: 16585319
[TBL] [Abstract][Full Text] [Related]
19. Accuracy of t-PA, u-PA, PAI-1 and PAI-2 estimation in human bile by ELISA kits.
Kondera-Anasz Z; Michalski A; Gil D; Gil B; Starzewski J; Gonciarz Z
Med Sci Monit; 2000; 6(3):616-7. PubMed ID: 11208381
[TBL] [Abstract][Full Text] [Related]
20. Urokinase and tissue plasminogen activators and their inhibitor PAI-1 in human tumors.
Gershtein ES; Kushlinskii NE
Bull Exp Biol Med; 2001 Jan; 131(1):67-72. PubMed ID: 11329087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
